Is Keflex Effective Against Gram-Positive Bacteria in UTI?
Yes, Keflex (cephalexin) is effective against most Gram-positive bacteria causing UTIs, including Staphylococcus aureus (including penicillinase-producing strains), Streptococcus pneumoniae, and Streptococcus pyogenes, but it is NOT effective against enterococci (Enterococcus faecalis), which are a common Gram-positive cause of complicated UTIs. 1
Spectrum of Activity
According to the FDA label, cephalexin demonstrates bactericidal activity against the following Gram-positive organisms in UTIs 1:
- Staphylococcus aureus (including penicillinase-producing strains) - COVERED
- Streptococcus pneumoniae (penicillin-susceptible strains) - COVERED
- Streptococcus pyogenes - COVERED
Critical Limitation: Enterococcal Resistance
The most important caveat is that methicillin-resistant staphylococci and most strains of enterococci (Enterococcus faecalis) are resistant to all cephalosporins, including cephalexin. 1 This is clinically significant because enterococci are common Gram-positive uropathogens, particularly in complicated UTIs, catheter-associated UTIs, and healthcare-associated infections 2.
Clinical Guideline Recommendations
Current 2024 guidelines provide nuanced recommendations for cephalosporin use in UTIs:
For Uncomplicated Cystitis
First-generation cephalosporins like cephalexin are listed as alternatives rather than first-line agents 3. The 2024 EAU guidelines suggest cephalosporins (e.g., cefadroxil) at 500 mg twice daily for 3 days, but only if local E. coli resistance is <20% 3.
For Pyelonephritis
First-generation cephalosporins represent reasonable first-line agents for pyelonephritis, but selection should depend on local resistance rates. 4 For oral therapy, cefpodoxime 200 mg twice daily for 10 days or ceftibuten 400 mg daily for 10 days are recommended 3. For parenteral therapy requiring hospitalization, ceftriaxone 1-2 g daily is the preferred empirical choice 4, 3.
Clinical Efficacy Data
Recent studies demonstrate good clinical outcomes with cephalexin for UTIs:
- A 2023 retrospective review showed 81.1% clinical success with twice-daily cephalexin for uncomplicated UTIs 5
- A 2025 study found no significant difference in treatment failure between twice-daily versus four-times-daily dosing (18.7% vs 15.0%, P=0.465) 6
- A 2023 pediatric study showed cephalexin covered 85.3% of lower UTI isolates 7
Practical Algorithm for Use
Use cephalexin for Gram-positive UTIs when:
- Culture confirms susceptible Staphylococcus aureus or Streptococcus species
- Patient has uncomplicated cystitis without risk factors for enterococcal infection
- Local resistance patterns show <20% resistance among E. coli (for empiric use)
Avoid cephalexin when:
- Enterococcal infection is suspected or confirmed (use ampicillin or vancomycin instead)
- Patient has complicated UTI with indwelling catheter (high enterococcal risk) 2
- Methicillin-resistant staphylococci are suspected 1
Dosing Considerations
For UTIs, cephalexin 500 mg twice daily appears as effective as four-times-daily dosing 6, improving adherence without compromising efficacy. The FDA label indicates that after a 500 mg dose, peak urine concentrations reach approximately 2200 μg/mL, with over 90% excreted unchanged in urine within 8 hours 1.
Common Pitfall
The most frequent error is prescribing cephalexin empirically for complicated UTIs or catheter-associated UTIs without considering enterococcal coverage. In these scenarios, approximately 30% of infections involve Gram-positive organisms, with Enterococcus faecalis being the second most common after Staphylococcus aureus 2, and cephalexin will fail against enterococci.